Fig. 1

Acute treatment with TPA-023, alone, and in combination with atypical APD, Lurasidone, rescued scPCP-induced NOR deficit in male C57BL/6J mice. a–c The effect of scVeh, subchronic phencyclidine (scPCP), and scPCP + TPA-023 (0.03 and 0.1 mg/kg) on AT, RT, and DI in scPCP-treated male C57BL/6J mice. Data are shown as mean ± S.E.M. of exploration time (s) n = 10 mice per group. a AT—the effect of acute administration of TPA-023 (0.03 and 0.1 mg/kg; i.p.) post-scPCP (10 mg/kg i.p. bid for 7 days followed by a 7-day drug-free period) on the exploration of a left and a right object in the 10-min AT in an NOR task in scPCP-treated male C57BL/6J mice; no significant effect in any of the groups tested. b RT—the effect of acute TPA-023 (0.03 and 0.1 mg/kg) post-scPCP (10 mg/kg) on the exploration of a novel and a familiar object in the 10-min RT in an NOR task in scPCP-treated male C57BL/6J mice; ***P < 0.001—significant increase in the time spent exploring the novel vs familiar object, Bonferroni t test. c DI—***P < 0.001—significant reduction in DI vs scVeh group; ^###P < 0.001—significant increase in DI vs scPCP group; ^^^P < 0.001—significant decrease in DI vs scPCP+TPA-023 (0.1 mg/kg; i.p.) group. d–f The effect of scVeh, scPCP, and scPCP + TPA-023 (0.03mg/kg; i.p.), scPCP+Lur (0.1 mg/kg; i.p.), and scPCP+TPA-023 (0.03 mg/kg; i.p.) + Lur (0.1 mg/kg; i.p.) on AT, RT, and DI in scPCP-treated male C57BL/6J mice. Data are shown as mean ± S.E.M. of exploration time (s) n = 10 mice per group. a AT—no significant difference in the exploration of left and right object between the groups; b RT—***P < 0.001—significant exploration of novel vs familiar object; c DI—***P < 0.001—significant reduction in DI vs vehicle-treated controls; ^###P < 0.001—significant increase in DI vs scPCP-treated C57BL/6J mice; ^^^P < 0.001—significant decrease in DI vs scPCP+TPA-023 (0.03 mg/kg)+Lur(0.1 mg/kg) group